Understanding the Link Between Statins and Muscle Pain
Approximately 10 percent of individuals who take statins to lower cholesterol experience unexplained muscle pains, leading many to discontinue these important medications. Recent research from Columbia University and the University of Rochester has shed light on the underlying mechanism behind statin-associated muscle symptoms (SAMS), revealing how these symptoms may be triggered by calcium influx into muscle cells.
Statins are commonly prescribed to reduce levels of LDL cholesterol in the blood, thereby lowering the risk of cardiovascular diseases like atherosclerosis. However, these drugs can also impact off-target molecules such as ryanodine receptor 1 (RyR1), a protein channel responsible for regulating calcium flow into muscles.
Using advanced imaging techniques like cryo-electron microscopy, researchers have identified how statins bind to RyR1, potentially disrupting the normal function of this calcium gate. This disruption can lead to calcium leakage into muscle cells, causing tissue damage and a range of symptoms including muscle pain, weakness, and cramps.
In some cases, individuals with certain RyR1 mutations may be at higher risk of severe complications such as malignant hyperthermia or rhabdomyolysis, where muscle breakdown products enter the bloodstream and can lead to kidney failure.
While not all cases of SAMS may be attributed to the leaky calcium gate mechanism, this research provides valuable insights into identifying individuals at risk of statin intolerance. With millions of adults in the US alone taking statins, understanding and addressing these side effects is crucial.
Lead author Andrew Marks emphasizes the importance of finding solutions for patients who experience statin-related muscle aches. Two potential approaches include redesigning statins to avoid binding to RyR1 while still effectively lowering cholesterol, or using experimental drugs like Rycal to mitigate the effects of statin-induced muscle weakness.
Published in the Journal of Clinical Investigation, this research offers hope for improving the tolerability and effectiveness of statin therapy for individuals at risk of SAMS.
